Weight Loss Pharmacotherapy: Current and Future Therapies.

The rising prevalence of obesity is of major concern. There are currently 5 Food and Drug Administration-approved medications for the treatment of obesity: orlistat, phentermine/topiramate, naltrexone/bupropion, liraglutide 3.0 mg, and semaglutide 2.4 mg. Surgical options such as bariatric surgery and endoscopic surgery induce more durable weight loss than pharmacotherapy or lifestyle interventions alone. However, patients often experience weight regain and weight loss plateau after surgery. The addition of multimodal or multihormonal pharmacotherapy is a promising tool to address these challenges. The optimal timing of obesity pharmacotherapy with surgical and endoscopic interventions requires further investigation.
Competing Interests: Disclosure J.O. Alemán is a consultant for Novo Nordisk and clinical advisory board member for Intellihealth. The authors declare that they have no relevant or material financial interests that relate to the data described in this study. Funding Doris Duke Charitable Foundation (JOA), American Heart Association 17- SFRN33490004 (JOA), NIH K08 DK117064 (JOA), NIH NHLBI P01 HL 160470-01A1 (JOA).
(Published by Elsevier Inc.)